← Leaderboards
Robert G Bennett
Omaha Va Medical Center
$703,836
Attributed
$703,836
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $250.2K · FY2007–24$500K$375K$250K$125K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$703,836 · 1
VA$0 · 3
By mechanism
R01$703,836 · 1
I01$0 · 2
IS1$0 · 1
Top collaborators
No co-investigators on record.
Most similar at Omaha Va Medical Center
Same institution · by research overlap
- Carol A Casey$7,212,221
Others in their field
Top investigators on “Liver Diseases”
- David Heimbrook · Leidos Biomedical Research, Inc.$183,557,534
- Constance Ann Benson · University Of California, San Diego$65,790,143
- Richard Douglas Moore · Johns Hopkins University$59,048,354
- Paul M. Ridker · Brigham And Women'S Hospital$55,416,022
- Michael S. Saag · University Of Alabama At Birmingham$50,288,385
- Larry Arthur$49,271,333
Research focus
Liver DiseasesPpar GammaPathway InteractionsRelaxin ReceptorTissuesAffectSignal PathwayLiver FibrosisReceptorRelaxinInjurySignal TransductionHormonesAgonistEnvironmentFibrosisLiverVeteransBaseCollagenHepatitisExcisionCirrhosisHepatic Stellate Cell
Grant awards (15)
ShEEP Request for a Confocal Laser Scanning Microscope$0
IS1 · FY2024 · VA · contact PI
The Role of Relaxin Signaling in Adipose Tissue Fibrosis and Function$0
I01 · FY2024 · VA · contact PI
The Role of Relaxin Signaling in Adipose Tissue Fibrosis and Function$0
I01 · FY2023 · VA · contact PI
The Role of Relaxin Signaling in Adipose Tissue Fibrosis and Function$0
I01 · FY2022 · VA · contact PI
Relaxin and PPAR gamma Activation for Liver Disease Treatment$0
I01 · FY2019 · VA · contact PI
Relaxin and PPAR gamma Activation for Liver Disease Treatment$0
I01 · FY2018 · VA · contact PI
Relaxin and PPAR gamma Activation for Liver Disease Treatment$0
I01 · FY2017 · VA · contact PI
Relaxin and PPAR gamma Activation for Liver Disease Treatment$0
I01 · FY2016 · VA · contact PI
Mechanisms of Antifibrotic Actions of Relaxin in the Liver$0
I01 · FY2014 · VA · contact PI
Mechanisms of Antifibrotic Actions of Relaxin in the Liver$0
I01 · FY2013 · VA · contact PI
Mechanisms of Antifibrotic Actions of Relaxin in the Liver$0
I01 · FY2012 · VA · contact PI
Mechanisms of Antifibrotic Actions of Relaxin in the Liver$0
I01 · FY2011 · VA · contact PI
RELAXIN FAMILY PEPTIDES AND HEPATIC FIBROSIS$226,800
R01 · FY2009 · AA · contact PI
RELAXIN FAMILY PEPTIDES AND HEPATIC FIBROSIS$226,800
R01 · FY2008 · AA · contact PI
RELAXIN FAMILY PEPTIDES AND HEPATIC FIBROSIS$250,236
R01 · FY2007 · AA · contact PI